FDA Approves ZELBORAF — Genentech, Inc.

Genentech, Inc. secured FDA approval today for ZELBORAF (vemurafenib), a targeted treatment for BRAF V600E mutation-positive melanoma, which is expected to capitalize on growing demand for precision oncology therapies. The oral medication is anticipated to position Genentech strongly in the rapidly evolving melanoma marketplace, providing a critical option for a patient subset that has historically lacked effective precision treatments.